Prosecution Insights
Last updated: October 02, 2026
Application No. 18/713,428

OIL-BASED COSMETIC

Non-Final OA §103
Filed
May 24, 2024
Priority
Dec 24, 2021 — JP 2021-210086 +1 more
Examiner
SANCHEZ, JUSTIN CHRISTOPHER
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
SHISEIDO Company, Ltd.
OA Round
1 (Non-Final)
89%
Grant Probability
Favorable
1-2
OA Rounds
11m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 89% — above average
89%
Career Allowance Rate
47 granted / 53 resolved
+28.7% vs TC avg
Moderate +10% lift
Without
With
+10.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
32 currently pending
Career history
80
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
34.6%
-5.4% vs TC avg
§102
16.6%
-23.4% vs TC avg
§112
34.6%
-5.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 53 resolved cases

Office Action

§103
DETAILED ACTION Claims 1-7, submitted 24 May 2024, are pending in the application and subject to examination in the instant Office Action. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-7 are rejected under 35 U.S.C. 103 as being unpatentable over Clavel (US PG-PUB 2018/0263890 A1) in view of Inoue et al (JP 2012-149041 A). As the original Inoue document is in Japanese and the Examiner does not read Japanese, the translated document provided by the Applicant will be cited as the English equivalent. Clavel teaches an anhydrous liquid composition comprising, in a physiologically acceptable medium, a) an oily phase comprising: i) at least one non-volatile oil and ii) at least one volatile hydrocarbon oil and b) at least one monoalcohol comprising from 2-8 carbon atoms and c) at least one lipophilic film-forming polymer chosen from: (i) silicone resins of MQ type, (ii) silsesquioxane resins, (iii) vinyl polymers grafted with a carbosiloxane dendrimer, (iv) their mixtures, and d) at least one particulate material, the said material composition comprising at least 15% by weight of non-volatile oils with respect to the total weight of the composition (Abstract; paragraph 0001; Claim 1). Additionally, Clavel teaches wherein the non-volatile silicone oil is a phenylated silicone oil and further wherein the silicone oil is trimethyl pentaphenyl trisiloxane (paragraphs 0055-0057 and 0062). This reference further teaches wherein the oily phase comprises at least one non-volatile oil in a proportion of at least 15% by weight, prefereably of at least 30% by weight with respect to the total weight of the composition (paragraph 0021) which reads on the percent by mass of the claimed component (A). Specifically, Clavel teaches a specific embodiment wherein the non-volatile oil comprises a silicone resin of MQ type of trimethylsiloxysilicate (paragraph 0218; Claim 15) and a silsesquioxane resin having an average siloxane unit of formula R1nSiO(4-n)2 where each R1 independently denotes a hydrogen atom or a C1-C10 alkyl group where it is preferred that the R1 is a C1-C4 alkyl (paragraph 0114-0115). This reads on the limitations of instant claims 2-3 has when R1 is methyl, the silsesquioxane is a polymethylsilsesquioxane and the MQ resin is trimethylsiloxysilicate. Regarding claim 4, Clavel teaches wherein the hydrocarbon oil is a synthetic ester of fatty acid (i.e., diisostearyl malate) (paragraphs 0049, 0051; Claim 4). This also reads on the limitations of claim 5 which further limit the ester oil component to diisostearyl malate. With respect to claim 6, Clavel teaches that the composition can contain additional cosmetic ingredients such as lipophilic gelling agents (paragraph 0266). While Clavel does not teach wherein the lipophilic gelling agents are a glyceryl ester, Inoue teaches a cosmetic composition comprising 15-80 mass percent of a phenyl-modified silicone and a liquid ester compound (paragraph 0009) further comprising a gelling agent, component (C) (paragraph 0022). Inoue also teaches that the oily gelling agent is not particularly limited as long as it is usually used in cosmetics and offers examples of glyceryl esters such as deca (behenic acid/ capric acid) polyglyceryl-8 and tri (behenic acid/ isostearic acid/ eicosanedoic acid) glyceryl (paragraph 0028). It would have been prima facie obvious for a person having ordinary skill in the art to combine the teachings of Clavel with the teachings of Inoue to form an oil-based cosmetic composition comprising a non-volatile oil and a volatile oil wherein the non-volatile oil comprises a silicone resin, trimethylpentaphenyltrisoloxane and an ester oil, further comprising a thickening agent wherein the thickening agent is a glyceryl ester. A person having ordinary skill in the art would have an expectation of success because Inoue teaches that when the thickening agent is 1-10 percent by mass of the total amount of the lip cosmetic, the retention ability of the oil is good, the stability over time is good and the dispersibility of the phenyl-modified silicone component is good (paragraph 0029). Thus, it would have been prima facie obvious for a person having ordinary skill in the art, prior to the effective filing date of the instant application, to combine the teachings of Clavel with the teachings of Inoue to arrive at the instantly claimed invention. With regards to claim 7, Clavel teaches wherein the anhydrous liquid composition further comprises a metal powder, such as silica-coated aluminum (aluminum silicate), at a range of 4% to 12% by weight with respect to the total weight of the composition. This reads on the limitations of claim 7 which require that the amount of powder excluding a colorant is 8% by mass or less. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JUSTIN CHRISTOPHER SANCHEZ whose telephone number is (703)756-5336. The examiner can normally be reached Monday -Friday (0730-1700). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. JUSTIN CHRISTOPHER SANCHEZ Examiner Art Unit 1622 /J.C.S./Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

May 24, 2024
Application Filed
Jul 01, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746216
COMBINATORY TREATMENT
3y 11m to grant Granted Sep 29, 2026
Patent 12741976
QUINOXALINE DERIVATIVES AND USES THEREOF
3y 1m to grant Granted Sep 22, 2026
Patent 12735573
NEAR INFRARED DYES FOR BIOLOGICAL IMAGING AND OPTOELECTRONIC DEVICES
2y 12m to grant Granted Sep 15, 2026
Patent 12734147
NEURODEVELOPMENTAL DISORDER THERAPY
2y 10m to grant Granted Sep 15, 2026
Patent 12721840
METHODS OF TREATING GLIOBLASTOMA MULTIFORME USING COMBINATION THERAPY
3y 11m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
89%
Grant Probability
99%
With Interview (+10.2%)
3y 3m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 53 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month